Caris Life Sciences Analyst Price Targets - Benzinga

Caris Life Sciences Inc

CAINASDAQ

Trade with Public

Trade with Public

$31.75

-0.23-0.72%

近くで: Sep 25, 5:00 PM EST

$31.21

-0.77-2.41%

プレマーケット: 7:32 AM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成配当比較オプション株式レポート

Caris Life Sciences Analyst Price Targets

Wall Street analyst price targets and consensus rating for Caris Life Sciences (CAI).

Price Target Range — 5 Quarters

Analyst Consensus — 11 Analysts

8Buy

3Hold

Consensus RatingBuy# Analysts11Avg. Consensus PT$29Upside to Avg. PT-7.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

すべての評価を見る →

Date	Firm	Analyst	Action	Rating Change	Price Target
Sep 9, 2026	UBS	Doug Schenkel	Initiate	Neutral	$28
Aug 6, 2026	BTIG	Mark Massaro	PT Raise	Buy	$32→$33
Aug 6, 2026	Evercore ISI Group	Vijay Kumar	PT Raise	Outperform	$25→$26
Jul 6, 2026	Evercore ISI Group	Vijay Kumar	PT Cut	Outperform	$30→$25
Jul 2, 2026	BTIG	Mark Massaro	Maintained	Buy	$32
Jun 2, 2026	Wolfe Research	Mike Polark	Assumes	Peer Perform	—
May 8, 2026	Citigroup	Patrick Donnelly	PT Cut	Buy	$35→$28
May 8, 2026	JP Morgan	Casey Woodring	PT Cut	Overweight	$35→$30
May 8, 2026	BTIG	Mark Massaro	PT Cut	Buy	$38→$32
Apr 13, 2026	Jefferies	Tycho Peterson	Initiate	Buy	$28
Apr 10, 2026	Piper Sandler	David Westenberg	Initiate	Neutral	$21
Apr 6, 2026	Evercore ISI Group	Vijay Kumar	PT Cut	Outperform	$34→$30
Mar 13, 2026	Canaccord Genuity	Kyle Mikson	PT Cut	Hold	$30→$22
Feb 27, 2026	Evercore ISI Group	Vijay Kumar	PT Cut	Outperform	$38→$34
Feb 27, 2026	Baird	Catherine Schulte	PT Raise	Outperform	$26→$28
Feb 27, 2026	BTIG	Mark Massaro	PT Cut	Buy	$45→$38
Feb 17, 2026	Baird	Catherine Schulte	Initiate	Outperform	$26
Dec 22, 2025	Canaccord Genuity	Kyle Mikson	PT Raise	Hold	$28→$30
Dec 2, 2025	Canaccord Genuity	Kyle Mikson	Initiate	Hold	$28
Aug 13, 2025	Guggenheim	Subbu Nambi	PT Raise	Buy	$32→$36

More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Evercore ISI Group Maintains Outperform on Caris Life Sciences, Raises Price Target to $26

Evercore ISI Group analyst Vijay Kumar maintains Caris Life Sciences (NASDAQ:CAI) with a Outperform and raises the price target from $25 to $26.

Benzinga Newsdesk

PRO
BTIG Reiterates Buy on Caris Life Sciences, Maintains $32 Price Target

BTIG analyst Mark Massaro reiterates Caris Life Sciences (NASDAQ:CAI) with a Buy and maintains $32 price target.

Benzinga Newsdesk

PRO
Wolfe Research Assumes Caris Life Sciences at Peer Perform

Wolfe Research analyst Mike Polark assumes Caris Life Sciences (NASDAQ:CAI) with a Peer Perform rating.

Benzinga Newsdesk

PRO
Citigroup Maintains Buy on Caris Life Sciences, Lowers Price Target to $28

Citigroup analyst Patrick Donnelly maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and lowers the price target from $35 to $28.

Benzinga Newsdesk

PRO
JP Morgan Maintains Overweight on Caris Life Sciences, Lowers Price Target to $30

JP Morgan analyst Casey Woodring maintains Caris Life Sciences (NASDAQ:CAI) with a Overweight and lowers the price target from $35 to $30.

Benzinga Newsdesk

PRO
BTIG Maintains Buy on Caris Life Sciences, Lowers Price Target to $32

BTIG analyst Mark Massaro maintains Caris Life Sciences (NASDAQ:CAI) with a Buy and lowers the price target from $38 to $32.

Benzinga Newsdesk